Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
Read More
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Cecilia BrownPrint | November 10, 2023
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
Melissa BadamoAcute Lymphoblastic Leukemia | November 6, 2023
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Cecilia BrownAcute Lymphoblastic Leukemia | October 3, 2023
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Advertisement
Cecilia BrownAcute Lymphoblastic Leukemia | October 2, 2023
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | September 27, 2023
Researchers conducted the study because the "optimal treatment strategy for these patients is still a matter of debate.”
Cecilia BrownAcute Lymphoblastic Leukemia | September 26, 2023
JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase.
Cecilia BrownAcute Lymphoblastic Leukemia | September 20, 2023
Researchers retrospectively analyzed treatment outcomes of 69 patients with relapsed or refractory CRLF2-rearranged B-ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | September 20, 2023
Low hypodiploidy “defines a rare subtype” of B-cell ALL with a “dismal outcome.”
Karun Neupane, MDVideo Insights | September 10, 2023
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 7, 2023
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
Cecilia BrownAcute Lymphoblastic Leukemia | September 6, 2023
The award is the society’s “most prestigious award" and “serves to honor those that have been pioneers in their work."
Leah LawrenceAcute Lymphoblastic Leukemia | September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Leah LawrenceMeeting News | September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 5, 2023
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas. 
Cecilia BrownAcute Lymphoblastic Leukemia | August 29, 2023
Investigators studied mechanisms of resistance to BH3 mimetics to “develop rational combination strategies" for T-cell ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | August 9, 2023
The researchers reported that 46.7% of patients had a BMI in the overweight or obese range.
Cecilia BrownAcute Lymphoblastic Leukemia | July 31, 2023
Induction chemotherapy failure occurred in 10.3% of cases and was significantly associated with increasing age.
Advertisement
Advertisement
Editorial Board